BACKGROUND: A functional repeat polymorphism in the SNCA promoter (REP1) conveys susceptibility for Parkinson disease (PD). There is also increasing evidence that single-nucleotide polymorphisms (SNPs) elsewhere in the gene are associated with PD risk. OBJECTIVES: To further explore the association of common SNCA SNPs with PD susceptibility, to determine whether evidence of allelic heterogeneity exists, and to examine the correlation between PD-associated variants and plasma α-synuclein levels. DESIGN: Two-tiered analysis. SETTING: Academic research. PATIENTS: Patients and control subjects from the NeuroGenetics Research Consortium. MAIN OUTCOME MEASURES: We performed a 2-tiered analysis of 1956 patients with PD and 2112 controls from the NeuroGenetics Research Consortium using a comprehensive tag SNP approach. Previously published REP1 genotypes were also included. Plasma α-synuclein was assayed in 86 patients with PD and 78 controls using a highly sensitive Luminex assay. RESULTS: Five of 15 SNPs genotyped were associated with PD under an additive model in tier 1 (α = .05). Of these, 4 were successfully replicated in tier 2. In the combined sample, the most significant marker was rs356219 (odds ratio, 1.41; 95% confidence interval, 1.28-1.55; P = 1.6 × 10(-12)), located approximately 9 kilobases downstream from the gene. A regression model containing rs356219 alone best fit the data. The linkage disequilibrium correlation coefficient between this SNP and REP1 was low (r(2) = 0.09). The risk-associated C allele of rs356219 was also correlated with higher transformed plasma α-synuclein levels in patients under an adjusted additive model (P = .005). CONCLUSIONS: Our data suggest that 1 or more unidentified functional SNCA variants modify risk for PD and that the effect is larger than and independent of REP1. This variant(s), tagged by rs356219, might act by upregulating SNCA expression in a dose-dependent manner.
BACKGROUND: A functional repeat polymorphism in the SNCA promoter (REP1) conveys susceptibility for Parkinson disease (PD). There is also increasing evidence that single-nucleotide polymorphisms (SNPs) elsewhere in the gene are associated with PD risk. OBJECTIVES: To further explore the association of common SNCA SNPs with PD susceptibility, to determine whether evidence of allelic heterogeneity exists, and to examine the correlation between PD-associated variants and plasma α-synuclein levels. DESIGN: Two-tiered analysis. SETTING: Academic research. PATIENTS: Patients and control subjects from the NeuroGenetics Research Consortium. MAIN OUTCOME MEASURES: We performed a 2-tiered analysis of 1956 patients with PD and 2112 controls from the NeuroGenetics Research Consortium using a comprehensive tag SNP approach. Previously published REP1 genotypes were also included. Plasma α-synuclein was assayed in 86 patients with PD and 78 controls using a highly sensitive Luminex assay. RESULTS: Five of 15 SNPs genotyped were associated with PD under an additive model in tier 1 (α = .05). Of these, 4 were successfully replicated in tier 2. In the combined sample, the most significant marker was rs356219 (odds ratio, 1.41; 95% confidence interval, 1.28-1.55; P = 1.6 × 10(-12)), located approximately 9 kilobases downstream from the gene. A regression model containing rs356219 alone best fit the data. The linkage disequilibrium correlation coefficient between this SNP and REP1 was low (r(2) = 0.09). The risk-associated C allele of rs356219 was also correlated with higher transformed plasma α-synuclein levels in patients under an adjusted additive model (P = .005). CONCLUSIONS: Our data suggest that 1 or more unidentified functional SNCA variants modify risk for PD and that the effect is larger than and independent of REP1. This variant(s), tagged by rs356219, might act by upregulating SNCA expression in a dose-dependent manner.
Authors: M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum Journal: Science Date: 1997-06-27 Impact factor: 47.728
Authors: Todd L Edwards; William K Scott; Cherylyn Almonte; Amber Burt; Eric H Powell; Gary W Beecham; Liyong Wang; Stephan Züchner; Ioanna Konidari; Gaofeng Wang; Carlos Singer; Fatta Nahab; Burton Scott; Jeffrey M Stajich; Margaret Pericak-Vance; Jonathan Haines; Jeffery M Vance; Eden R Martin Journal: Ann Hum Genet Date: 2010-01-08 Impact factor: 1.670
Authors: R Krüger; A M Vieira-Saecker; W Kuhn; D Berg; T Müller; N Kühnl; G A Fuchs; A Storch; M Hungs; D Woitalla; H Przuntek; J T Epplen; L Schöls; O Riess Journal: Ann Neurol Date: 1999-05 Impact factor: 10.422
Authors: Matt Farrer; Jennifer Kachergus; Lysia Forno; Sarah Lincoln; Deng-Shun Wang; Mary Hulihan; Demetrius Maraganore; Katrina Gwinn-Hardy; Zbigniew Wszolek; Dennis Dickson; J William Langston Journal: Ann Neurol Date: 2004-02 Impact factor: 10.422
Authors: D W Miller; S M Hague; J Clarimon; M Baptista; K Gwinn-Hardy; M R Cookson; A B Singleton Journal: Neurology Date: 2004-05-25 Impact factor: 9.910
Authors: Colton Linnertz; Michael W Lutz; John F Ervin; Jawara Allen; Natalie R Miller; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek Journal: Hum Mol Genet Date: 2014-04-28 Impact factor: 6.150
Authors: Min Shi; Changqin Liu; Travis J Cook; Kristin M Bullock; Yanchun Zhao; Carmen Ginghina; Yanfei Li; Patrick Aro; Romel Dator; Chunmei He; Michael J Hipp; Cyrus P Zabetian; Elaine R Peskind; Shu-Ching Hu; Joseph F Quinn; Douglas R Galasko; William A Banks; Jing Zhang Journal: Acta Neuropathol Date: 2014-07-06 Impact factor: 17.088